Under construction – not a live service
Sign in
Not yet taking people in SpainPhase 1

Testing TT125-802 for Relapsed or Refractory Multiple Myeloma

Tests TT125-802, alone or with other drugs, in adults with multiple myeloma.

Key facts

Who runs it
TOLREMO therapeutics AG
Where
Barcelona, Salamanca, and Sevilla, SpainSee the 3 sitesAlso in 1 other country, 2 sites
Registry title
A Phase 1 Study of TT125-802 as Monotherapy and in Combination with Pomalidomide and Dexamethasone in Participants with Multiple Myeloma
Status
Not yet recruiting
Phase
Phase 1
People taking part
25 people, planned
Started
1 Sept 2026
Expected to end
31 Mar 2029
Type of study
Interventional
Record updated
28 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with multiple myeloma that came back or stopped responding to treatment. It tests TT125-802 alone and with pomalidomide and dexamethasone.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Relapsed and refractory multiple myeloma (the cancer came back or no longer responds to treatment).

Where in Spain

Also in 1 other country, 2 sites

  • Hospital Universitari Vall d'HebronBarcelona, SpainNot yet recruiting
  • Complejo Asistencial Universitario de SalamancaSalamanca, SpainNot yet recruiting
  • University Hospital Virgen Del Rocio S.L.Sevilla, SpainNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Testing TT125-802 for Relapsed or Refractory Multiple MyelomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
28 August 2026